… for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung
cancer (NSCLC). However, data on the use of afatinib in patients with poor performance status (…

… For example, most of the older patients and patients with poor PS included in the current
study were treated with gefitinib or erlotinib. In addition, the sample size was relatively small, …

… in patients with poor performance status (PS) are unknown. … the performance status of each
patient during treatment. Each line shows the change in performance status (PS) of a patient …

… patient-reported outcomes to predict survival across the disease trajectory for patients with …
In this study, we validated the model to also predict the risk for having low performance status …

… performance status of critically ill cancer patients 2 … patients to mortality of patients without
cancer. Further, we aimed to identify factors associated with 2-year mortality in cancer patients. …

… Intriguingly, despite the increasing sophistication and cost of contemporary cancer care, 5,6
evaluation of patient performance status (PS)—an integral aspect of treatment selection, …

… and thereby downgrade a patient’s performance status. Coupled with … for patients with better
performance status, they may have a more optimistic bias in determining performance status …

… have enrolled patients with performance status (PS) 0–1. However, around 18% of patients
with NSCLC are PS2, and the activity and safety of pembrolizumab in these patients is …

… Performance status (PS) is one of the most common eligibility criteria, often resulting in
exclusion of patients from trial participation and leading to clinical trial populations that are not …

… Performance status (PS) of a patient is the assessment of level of … for patients with advanced
malignancy. It is crucial to thoroughly assess and accurately document PS for each patient …